The Royal London Hospital (Barts Health NHS Trust)
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Willemsen, Ruben
Meld-ATG, NCT04509791 / 2019-003265-17: MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

Completed
2
114
Europe
Anti-Human Thymocyte Immunoglobulin, Rabbit, ATG
Universitaire Ziekenhuizen KU Leuven
Diabetes Mellitus, Type 1
12/24
12/24
CapOGTT, NCT06815081: Capillary OGTT Study

Recruiting
N/A
90
Europe
University of Oxford, University of Bristol, Yale University, Oxford University Hospitals NHS Trust, Nottingham University Hospitals NHS Trust, Cardiff and Vale University Health Board, Royal London Hospital, Barts Health NHS Trust
Type 1 Diabetes (T1D)
08/25
08/25
YESS, NCT04252001: Growing up With the Young Endocrine Support System (!)

Not yet recruiting
N/A
160
Europe
YESS! game, Snake '97, control game, Transition-toolkit
dr. Laura C. G. de Graaff-Herder
Congenital Adrenal Hyperplasia, Hypogonadotropic Hypogonadism, Growth Hormone Deficiency, Combined Pituitary Hormone Deficiency, Turner Syndrome, Klinefelter Syndrome, Addison's Disease, Androgen Insensitivity Syndrome, Thyroid Dysgenesis
12/26
12/26

Download Options